EUROIMMUN

EUROIMMUN

Lübeck, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

EUROIMMUN is a leading, revenue-generating diagnostics company with a core focus on serological testing for autoimmune, infectious, and neurological diseases. The company leverages a broad technology platform encompassing immunofluorescence assays (IFA), ELISA, and chemiluminescence immunoassays (ChLIA), supported by automated instruments. As a subsidiary of Revvity, Inc., it benefits from global commercial scale while continuing to innovate, particularly in the high-growth area of neurological autoantibody testing.

Autoimmune DiseasesInfectious DiseasesAllergyNeurologyEndocrinology

Technology Platform

Multi-platform immunoassay developer: Indirect Immunofluorescence Assays (IFA) including cell-based assays (CBA), Enzyme-Linked Immunosorbent Assays (ELISA), and Chemiluminescence Immunoassays (ChLIA). Supported by automated instruments like UNIQO160 (IFA) and IDS i20 (random access ChLIA).

Opportunities

High-growth potential in neurological autoantibody testing driven by increased clinical recognition.
Expansion in emerging markets like Brazil and Latin America.
Leveraging the IDS i20 automated platform to capture share in the high-throughput laboratory segment.

Risk Factors

Intense competition from large IVD conglomerates and specialized firms.
Regulatory hurdles, especially under the new EU IVDR.
Dependency on parent company Revvity for strategic direction and resources.

Competitive Landscape

Operates in a competitive global IVD market dominated by large players like Roche, Abbott, Siemens, and Thermo Fisher. Holds a strong, specialized position in autoimmune and neurological serology, competing with companies like Werfen (Inova), AESKU.Diagnostics, and Mayoly Spindler. Faces increasing competition in automation from the major platform vendors.